- Home
- MXCT vs ITOS Comparison
MXCT vs ITOS Comparison
Compare MXCT & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- ITOS
- Stock Information
- Founded
- MXCT 1999
- ITOS 2011
- Country
- MXCT United States
- ITOS United States
- Employees
- MXCT N/A
- ITOS N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MXCT Health Care
- ITOS Health Care
- Exchange
- MXCT Nasdaq
- ITOS Nasdaq
- Market Cap
- MXCT 375.0M
- ITOS 271.1M
- IPO Year
- MXCT 2021
- ITOS 2020
- Fundamental
- Price
- MXCT $4.11
- ITOS $7.47
- Analyst Decision
- MXCT Strong Buy
- ITOS Strong Buy
- Analyst Count
- MXCT 2
- ITOS 3
- Target Price
- MXCT $9.50
- ITOS $21.33
- AVG Volume (30 Days)
- MXCT 558.7K
- ITOS 519.8K
- Earning Date
- MXCT 11-06-2024
- ITOS 11-12-2024
- Dividend Yield
- MXCT N/A
- ITOS N/A
- EPS Growth
- MXCT N/A
- ITOS N/A
- EPS
- MXCT N/A
- ITOS N/A
- Revenue
- MXCT $45,599,000.00
- ITOS $35,000,000.00
- Revenue This Year
- MXCT N/A
- ITOS $271.18
- Revenue Next Year
- MXCT $21.27
- ITOS N/A
- P/E Ratio
- MXCT N/A
- ITOS N/A
- Revenue Growth
- MXCT 19.85
- ITOS N/A
- 52 Week Low
- MXCT $3.17
- ITOS $7.09
- 52 Week High
- MXCT $5.55
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- MXCT 55.35
- ITOS 37.42
- Support Level
- MXCT $3.98
- ITOS $7.09
- Resistance Level
- MXCT $4.41
- ITOS $7.51
- Average True Range (ATR)
- MXCT 0.27
- ITOS 0.38
- MACD
- MXCT -0.00
- ITOS -0.03
- Stochastic Oscillator
- MXCT 54.64
- ITOS 25.68
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.